Member News

Design + Industry is now ISO 13485:2016 certified

BioMelbourne Network member Design + Industry (D+I) is proud to announce that they have achieved ISO 13485:2016 certification — the culmination of a four-year effort and recognition of their commitment to design and engineering excellence in the development…

2019 ARCS Annual Conference: call for session and program proposals extended

Interested parties from industry, research institutions, government and academia involved in development through to commercialisation of therapeutics (from bench to bedside) are invited to submit session proposals and program suggestions for the 2019 ARCS Annual Conference to be…

BioEYES looking for industry partners

3 December 2018  BioEYES Australia is a science outreach program that covers curricula in genetics, cell biology and developmental biology, but more importantly excites students about the thrill of scientific discovery. Over a 1 week incursion, students set…

ARC Centre for Personalised Therapeutics Technologies launches in Melbourne

22 November 2018 The ARC Centre for Personalised Therapeutics Technologies launched in Melbourne this week. The centre, headquartered at the Department of Pharmacology and Therapeutics at the University of Melbourne, aims to advance and deploy new technologies that will remove…

Novartis and BioCurate announce first collaboration to accelerate early stage drug discovery

31 October 2018 Biomedical research company BioCurate Pty Ltd and Novartis today announced that they will collaborate on early stage drug discovery projects that have potential to address an unmet need. This collaboration marks BioCurate’s first with the…

Watermark a first-mover with customised website live chat platform

Being on the leading edge of innovation and intellectual property, Watermark is paving the digital path for IP attorney and legal services firms with the unveiling of a website chat bot. Executive General Manager Mark Bisset says the…

Immutep enters into clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany, and Pfizer

Immutep Limited is pleased to announce that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc., to evaluate the combination of Immutep’s lead immunotherapy product candidate eftilagimod alpha…

Burnet’s qDOS Lab a new approach to bringing innovative technologies to market

Fast-tracking innovative technologies through early proof-of-concept and feasibility stages is a key aim of Burnet Institute’s new initiative, the Quick Development of Solutions Lab (qDOS Lab). Nurturing technologies through key early-stage development phases by adopting a market led approach is a primary focus…

Grimwade Medal Oration: Prof Randy Schekman – From Pond Scum to Stockholm

Thursday 20 September, 5.00–6.00 pm | Bio21 Institute Auditorium This year’s Grimwade Medallist is 2013 Nobel Laureate Prof Randy W Schekman, investigator of the Howard Hughes Medical Institute, Chair of the Advisory Council for the Aligning Science Across…

What to do when an R&D tax incentive claim goes bad

The R&D tax incentive program is the Government’s largest program designed to support business innovation. It has been reviewed multiple times, with each review concluding it provides significant benefits to the Australian economy, far beyond the cost. AusIndustry…

IT in healthcare: getting your product to market

Thursday, 20 September 2018 | 9 am–1 pm A free workshop hosted by the Department of Industry, Innovation and Science Entrepreneurs’ Programme IT in healthcare applications, devices and systems has seen rapid growth and expansion in recent times. The…

Job: Senior Consultant – Market Access Lead

New growth opportunity Market leading company Diversity of projects The company Our client is integral to all stages of the product development cycle and subsequent success for international & Australasian companies across the healthcare landscape. Their clients include…

Home

News & opinion

Member Directory

Events